"“No magic wand” for Novo Nordisk, as CagriSema pen supply rumours swirl" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site ...

The U.S. Food and Drug Administration has approved Supernus Pharmaceuticals' drug-device combination to treat movement-related symptoms of Parkinson's disease, the drugmaker said on Tuesday.

The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a currently approved medicine but still didn't surpass it. Since Ozempic blasted onto the stage in 2017 with ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

CagriSema-treated patients achieved superior weight loss compared with those who received cagrilintide 2.4mg, semaglutide 2.4mg or placebo. Topline data were announced from a phase 3 trial ...

Novo Nordisk’s shares recovered some ground on Monday after a 27% slump on Friday in response to an underwhelming set of results from a Phase III trial of its new weight-loss drug CagriSema ...

Less-than-stellar phase 3 results with Novo Nordisk's highly anticipated obesity therapy CagriSema have caused its shares to fall by over a fifth, wiping around $94 billion off its market cap.

Second, the medicine everyone thought would take over the industry, Novo Nordisk's CagriSema, did not perform as well as expected in a phase 3 study. CagriSema could still be a commercial success ...

The Street broadly expected the Redefine-1 trial of CagriSema to show ~25% weight loss, raising the benchmark injectables in development. Viking Therapeutics highlighted new clinical data from its ...

05:57 EST Novo Nordisk (NVO) says patients on Cagrisema lost 22.7% of weight in trial Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks! Easily identify outperforming ...